17072-38-7

Basic information

• Product Name: 4-ethyl-1H-pyrazole
• Synonyms: 4-ethyl-1H-pyrazole
• CAS NO: 17072-38-7
• Molecular Formula: C₅H₈N₂
• Molecular Weight: 96.13042
• Mol File: 17072-38-7.mol

Chemical Properties

• Boiling Point: 122 °C(Press: 16 Torr)
• Appearance: /
• Density: 0.9862 g/cm3
• PKA: 14.84±0.50(Predicted)
• CAS DataBase Reference: 4-ethyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ethyl-1H-pyrazole(17072-38-7)
• EPA Substance Registry System: 4-ethyl-1H-pyrazole(17072-38-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 17072-38-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-ethyl-1H-pyrazole is used as a building block for the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Research Applications:
4-ethyl-1H-pyrazole is used as a ligand in coordination chemistry and as a reagent in organic synthesis, aiding in the advancement of scientific research and the discovery of new compounds.
It is important to handle 4-ethyl-1H-pyrazole with caution due to its potential hazards if not properly managed, and it exhibits moderate solubility in water and relative stability under standard conditions.

Upstream product

• 342909-67-5 3-ethoxy-2-ethyl-prop-2-enal 
• 85907-40-0 3-(dimethylamino)-2-ethyl-prop-2-enal 
• 57121-49-0 4-ethynyl-1H-pyrazole 
• 900164-93-4 4-((trimethylsilyl)ethynyl)-1Η-pyrazole 

Downstream Products

• 1218920-81-0 C₂₉H₂₈ClN₇ 

Relevant articles and documents

19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

PURINE DERIVATIVES AS A2A RECEPTOR AGONISTS

A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof.and their preparation and use as A2A receptor agonists

PURINE DERIVATIVES ACTING AS A2A RECEPTOR AGONISTS

Compounds of formula (I) in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Synthesis of the silver(I) complex of CH2[CH(pz 4Et)2]2 containing the unprecedented [Ag(NO3)4]3- anion: A general method for the preparation of 4-(alkyl)pyrazoles

A general two-step method for the syntheses of 4-(alkyl)pyrazoles has been developed. The first step involves the reaction between organyl diethylacetals and the Vilsmeier reagent to give a mixture of ethoxy-and dimethylamino- acroleins. This mixture reacts directly with hydrazine monohydrogenchloride to yield the desired (4-substituted)pyrazoles. The 4-(phenyl)pyrazole derivative exhibited a markedly lower solubility in common organic solvents. In the solid state structure the phenyl and pyrazolyl groups are nearly coplanar and extensive intermolecular CH-π interactions organize the molecules in two-dimensional sheets that are held in a three dimensional arrangement by NH...N hydrogen bonds. Tetrakis[(4-ethyl)pyrazolyl]propane, CH 2[CH(pz4Et)2]2, was prepared by a transamination reaction and reacts with Ag(NO3) to yield a compound with a 4:3 metal:ligand mole ratio that when crystallized by diffusion of Et2O into an acetone solution produced [Ag2{μ-CH 2[CH(pz4Et)2]2}2] 3[Ag(NO3)4]2 (1). This complex contains dimeric units in which two silver cations are sandwiched between two CH2[CH(pz4Et)]2 ligands and the counterion is the unprecedented tetra(nitrato)argentate anion. ESI mass spectral data support the existence of both the cationic dimeric units and the [Ag(NO 3)4]- anion in solution.